|
|
 |
|
Viewing report
|
|
|
|
Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
GBI Research, July 2011, Pages: 132
“Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development” provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.
In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by a team of experts.
Scope
The scope of this report includes:
- Profiles of promising late stage pipeline molecules across various therapy areas
- Analysis of safety, efficacy, mechanism of actions of major pipeline drugs targeted at major therapy areas
- Comparison of late stage drugs based on safety, efficacy, mechanism of action, unmet need targeted and stage of disease targeted
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Build effective strategies to launch their pipeline products by identifying geographies with high potential for growth.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
